Internal Medicine, Hematology & Oncology · Grand Rapids, MI
NPI
1639459860
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
145 Michigan St NE Ste 3100
Grand Rapids, MI, 49503
Phone (616) 954-9800
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
89,565 services
Medicare patients, 2024
413
Average age 72
Drug cost, 2024
$6.9M
2,103 prescriptions
Company payments, 2025
$2,011
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Colin A Hardin was code J1569 (injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg), 2,550 times for 12 patients. In total Colin A Hardin billed 89,565 services in 176 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-14.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2,550 | 12 | $36.10 | $92K |
| 36415 Venipuncture Blood Collection | Office | 868 | 192 | $8.56 | $7,433 |
| 85025 Blood Count | Office | 861 | 192 | $7.53 | $6,483 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 760 | 18 | $0.09 | $67.02 |
| 80053 Clinical Chemistry | Office | 459 | 144 | $10.35 | $4,751 |
| 88185 Surgical Pathology Examination | Office | 446 | 16 | $16.81 | $7,497 |
| 99214 Office E&M - Established | Office | 400 | 203 | $87.25 | $35K |
| 83615 Clinical Chemistry | Office | 212 | 108 | $5.92 | $1,255 |
| 96375 Injection Administration | Office | 189 | 31 | $10.91 | $2,062 |
| 82784 Immunoassay | Office | 176 | 38 | $9.11 | $1,604 |
| 96413 Chemotherapy Administration | Office | 142 | 34 | $92.52 | $13K |
| 96372 Injection Administration | Office | 129 | 37 | $10.41 | $1,343 |
| 82728 Clinical Chemistry | Office | 118 | 64 | $13.36 | $1,576 |
| 96415 Chemotherapy Administration | Office | 111 | 15 | $20.31 | $2,254 |
| 99233 Hospital E&M - Subsequent | Facility | 109 | 41 | $87.87 | $9,578 |
By year: 2022 $851K for 51,907 services; 2023 $963K for 81,952 services; 2024 $1.3M for 89,565 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 868 | 192 | $8.56 | $7,433 |
| 85025 Blood Count | 861 | 192 | $7.53 | $6,483 |
| 80053 Clinical Chemistry | 459 | 144 | $10.35 | $4,751 |
| 88185 Surgical Pathology Examination | 446 | 16 | $16.81 | $7,497 |
| 83615 Clinical Chemistry | 212 | 108 | $5.92 | $1,255 |
| 82784 Immunoassay | 176 | 38 | $9.11 | $1,604 |
| 82728 Clinical Chemistry | 118 | 64 | $13.36 | $1,576 |
| 83540 Clinical Chemistry | 102 | 60 | $6.34 | $647 |
| 84466 Clinical Chemistry | 100 | 60 | $12.50 | $1,250 |
| 83521 Immunoassay | 98 | 33 | $16.93 | $1,659 |
Medicare prescription drug claims, 2024
In 2024, the drug Colin A Hardin prescribed most often to Medicare patients was Acyclovir, with 433 prescriptions and refills. In total Colin A Hardin wrote 2,103 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 433 | 485 | 83 | $7,412 |
| Hydroxyurea Generic | 228 | 383 | 45 | $5,582 |
| Revlimid Lenalidomide | 128 | 128 | 19 | $2.1M |
| Dexamethasone Generic | 116 | 129 | 36 | $1,715 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 90 | 100 | 24 | $223 |
| Prednisone Generic | 83 | 96 | 28 | $303 |
| Allopurinol Generic | 78 | 119 | 37 | $683 |
| Prochlorperazine Maleate Generic | 64 | 64 | 45 | $929 |
| Jakafi Ruxolitinib Phosphate | 59 | 59 | Under 11 | $988K |
| Venclexta Venetoclax | 53 | 53 | 13 | $151K |
| Eliquis Apixaban | 49 | 53 | 13 | $30K |
| Ondansetron Odt Ondansetron | 47 | 47 | 25 | $496 |
| Lenalidomide Generic | 43 | 43 | Under 11 | $631K |
| Potassium Chloride Generic | 30 | 34 | Under 11 | $335 |
| Neulasta Pegfilgrastim | 30 | 30 | Under 11 | $200K |
Brand drugs: 532 claims; generic drugs: 1,571 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Colin A Hardin $2,011 ($2,011 in general payments such as food, travel and fees) from 32 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $210.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $210 |
| Merck Sharp & Dohme LLC MRK | 7 | $191 |
| GlaxoSmithKline, LLC. GSK | 13 | $190 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $169 |
| Genentech USA, Inc. ROG.SW | 9 | $153 |
| Abbvie Inc. ABBV | 5 | $107 |
| BeOne Medicines USA, Inc. ONC | 3 | $100 |
| Celgene Corporation BMY | 4 | $91.55 |
| Daiichi Sankyo Inc. 4568.T | 4 | $89.82 |
| Incyte Corporation INCY | 4 | $83.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.